This system is an integrated, multi-module AI platform for hemodialysis, incorporating heart failure risk prediction, dry-weight recommendation, hemoglobin (Hb) prediction, and a newly introduced intradialytic hypotension (IDH) prediction module in 2025. It continuously analyzes approximately 200 dialysis parameters with millisecond-level processing speed, providing real-time risk assessment and early warnings during treatment. The platform has been clinically deployed across 90 dialysis beds at Taipei Veterans General Hospital, with prospective data collection ongoing for validation.

The system represents the first clinical deployment of an integrated AI platform comprising four predictive modules, with millisecond-level real-time computation enabling simultaneous multi-dimensional risk monitoring during dialysis. Studies have shown that intradialytic hypotension (IDH) prediction can provide warnings 15–75 minutes in advance. The system also demonstrates high accuracy in heart-failure risk prediction, significantly reduced error in dry-weight estimation, and hemoglobin (Hb) prediction to support renal anemia management, underscoring the breakthrough potential of AI in dialysis safety and precision medicine.

Taiwan has more than 90,000 dialysis patients, representing a substantial and ongoing healthcare need. Real-time AI prediction can help mitigate acute complications and reduce overall costs. The system has already been deployed in clinical practice and is positioned for nationwide scaling and international adoption. Musheng Technology is leading efforts toward SaMD certification and commercialization, through software licensing and technology transfer, with the goal of accelerating adoption and establishing the system as a compliant, market-ready AI solution to enhance dialysis safety.